Michael Abramoff

Michael Abramoff developed the first FDA-authorized fully autonomous AI diagnostic system (IDx-DR) and has established the regulatory and validation framework for deploying AI diagnostic tools in clinical practice, methodology that is now being applied to cancer screening and decision support AI tools. His work on demonstrating the clinical safety and efficacy of autonomous AI systems through prospective clinical trials has created a blueprint for the regulatory approval of oncology AI decision support tools. He continues to advance the science of AI clinical validation and real-world performance monitoring.